AstraZeneca lung cancer drug approved for new dosing regimen in EU, UK

British drugmaker AstraZeneca said on Friday that its cancer drug Imfinzi had been approved in Europe and Britain for a spaced-out, fixed-dose regimen for a common type of lung cancer, to help reduce the frequency of hospital visits.

The company said that an additional dosing option of a 1,500mg fixed dose every four weeks was approved for use in adults with advanced non-small cell lung cancer where tumours cannot be surgically removed.